Autopsy report · NCT01666743

Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia

“Change in strategy.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Forest Laboratories

Sponsor type

Industry

Conditions

Community-Acquired Bacterial Pneumonia (CABP)

Interventions

Ceftaroline fosamil

Participants

0

Trials that died the same way

• Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
  “Strategy Change” (90% match in meaning)
• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (77% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (75% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (75% match in meaning)
• Safety and Efficacy of Periodontal Surgery in Supra-alveolar-type Defects With or Without Straumann® Emdogain
  “Due to change in strategy and decision not to expand indication.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.